Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

Peel Hunt upgrades Hollywood Bowl to 'buy' after recent weakness

(Sharecast News) - Peel Hunt upgraded its stance on Hollywood Bowl on Wednesday to 'buy' from 'add' following recent share price weakness. It noted that over the 15 weeks to 12 January, like-for-like sales increased by 4.5% in the UK and 14.2% in Canada.

In the UK, pricing has been rising at a compound annual growth rate of 1-2% since 2019, during which sales and post-central EBITDA (IAS 17) per outlet have both risen by 35%, Peel Hunt said.

It also estimated that the relative cost of bowling at Hollywood Bowl has fallen to half the leisure sector average.

"Labour remains the largest source of cost inflation," said the broker. "However, utility costs are hedged until the end of 2027, and exposure to food and drink costs is limited, making non-labour costs reasonably certain.

"Forecast changes should be driven by sales, where we see upside potential, supported by the strength of new openings. Additionally, 1Q trading was ahead of our full-year forecast assumption of 1.3% and the company's 3% target (2% spend; 1% volume)."

Peel Hunt said it expects net debt to decrease from £29m to £11m this year, following £40m of capex, £28mcof dividends, and £10m of share buybacks.

"We anticipate LFL sales momentum to be the primary driver of forecasts and the share price," said the broker, which maintained its 340p price target.

At 1045 BST, the shares were up 3.2% at 274.50p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.